Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Hervé TillyFranck MorschhauserLaurie H SehnJonathan W FriedbergMarek TrněnýJeff P SharmanCharles HerbauxJohn M BurkeMatthew MatasarShinya RaiKoji IzutsuNeha Mehta-ShahLucie ObericAdrien ChauchetWojciech JurczakYuqin SongRichard GreilLarysa MykhalskaJuan M Bergua-BurguésMatthew C CheungAntonio PintoHo-Jin ShinGreg HapgoodEduardo MunhozPau AbrisquetaJyh-Pyng GauJamie HirataYanwen JiangMark YanCalvin LeeChristopher R FlowersGilles Andre SallesPublished in: The New England journal of medicine (2021)
Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP. (Funded by F. Hoffmann-La Roche/Genentech; POLARIX ClinicalTrials.gov number, NCT03274492.).